6 research outputs found

    PGE2 induces apoptosis of hepatic stellate cells and attenuates liver fibrosis in mice by downregulating miR-23a-5p and miR-28a-5p

    No full text
    MicroRNAs (miRNAs), small noncoding RNAs modulating messenger RNA (mRNA) and protein expression, have emerged as key regulatory molecules in chronic liver diseases, whose end stage is hepatic fibrosis, a major global health burden. Pharmacological strategies for prevention or treatment of hepatic fibrosis are still limited, what makes it necessary to establish a better understanding of the molecular mechanisms underlying its pathogenesis. In this context, we have recently shown that cyclooxygenase-2 (COX-2) expression in hepatocytes restricts activation of hepatic stellate cells (HSCs), a pivotal event in the initiation and progression of hepatic fibrosis. Here, we evaluated the role of COX-2 in the regulation of a specific set of miRNAs on a mouse model of CCl4 and bile duct ligation (BDL)-induced liver fibrosis. Our results provide evidence that COX-2 represses miR-23a-5p and miR-28-5p expression in HSC. The decrease of miR-23a-5p and miR-28-5p expression promotes protection against fibrosis by decreasing the levels of pro-fibrogenic markers α-SMA and COL1A1 and increasing apoptosis of HSC. Moreover, we demonstrate that serum levels of miR-28-5p are decreased in patients with chronic liver disease. These results suggest a protective effect exerted by COX-2-derived prostanoids in the process of hepatofibrogenesis.Fil: Brea, R.. Instituto de Investigaciones Biomédicas “Alberto Sols”; EspañaFil: Motiño, O.. Instituto de Investigaciones Biomédicas “Alberto Sols”; EspañaFil: Frances, Daniel Eleazar Antonio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Fisiología Experimental. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental; ArgentinaFil: García Monzón, C.. Instituto de Investigación Sanitaria Princesa; EspañaFil: Vargas, J.. Instituto de Investigación Sanitaria Princesa; EspañaFil: Fernández Velasco, M.. Instituto de Investigación Hospital Universitario La Paz; EspañaFil: Boscá, L.. Instituto de Investigaciones Biomédicas “Alberto Sols”; España. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; España. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares; EspañaFil: Casado, M.. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; España. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares; España. Instituto de Biomedicina de Valencia; EspañaFil: Martin Sanz, Paloma. Instituto de Investigaciones Biomédicas “Alberto Sols”; España. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; España. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares; EspañaFil: Agra, N.. Instituto de Investigaciones Biomédicas “Alberto Sols”; Españ
    corecore